These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 38940039)

  • 21. Alterations of hypoxia-induced factor signaling pathway due to mammalian target of rapamycin (mTOR) suppression in ovarian clear cell adenocarcinoma: in vivo and in vitro explorations for clinical trial.
    Hirasawa T; Miyazawa M; Yasuda M; Shida M; Ikeda M; Kajiwara H; Matsui N; Fujita M; Muramatsu T; Mikami M
    Int J Gynecol Cancer; 2013 Sep; 23(7):1210-8. PubMed ID: 23899586
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The combination of RAD001 and MK-2206 exerts synergistic cytotoxic effects against PTEN mutant gastric cancer cells: involvement of MAPK-dependent autophagic, but not apoptotic cell death pathway.
    Ji D; Zhang Z; Cheng L; Chang J; Wang S; Zheng B; Zheng R; Sun Z; Wang C; Zhang Z; Liu R; Zhang X; Liu X; Wang X; Li J
    PLoS One; 2014; 9(1):e85116. PubMed ID: 24416349
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
    Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
    Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma.
    Kling MJ; Griggs CN; McIntyre EM; Alexander G; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
    BMC Cancer; 2021 Sep; 21(1):1061. PubMed ID: 34565342
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Temsirolimus as a dual inhibitor of retinoblastoma and angiogenesis via targeting mTOR signalling.
    Chen Z; Yang H; Li Z; Xia Q; Nie Y
    Biochem Biophys Res Commun; 2019 Aug; 516(3):726-732. PubMed ID: 31253398
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of Mammalian Target of Rapamycin Pathway Activation in Basal Cell Carcinoma as a New Therapeutic Approach.
    Chang ALS; Brown R; Li S; Betancourt N; Teng J
    Am J Dermatopathol; 2024 Sep; 46(9):588-592. PubMed ID: 38648034
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor.
    Zou CY; Smith KD; Zhu QS; Liu J; McCutcheon IE; Slopis JM; Meric-Bernstam F; Peng Z; Bornmann WG; Mills GB; Lazar AJ; Pollock RE; Lev D
    Mol Cancer Ther; 2009 May; 8(5):1157-68. PubMed ID: 19417153
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Histone deacetylase inhibitor potentiated the ability of MTOR inhibitor to induce autophagic cell death in Burkitt leukemia/lymphoma.
    Dong LH; Cheng S; Zheng Z; Wang L; Shen Y; Shen ZX; Chen SJ; Zhao WL
    J Hematol Oncol; 2013 Jul; 6():53. PubMed ID: 23866964
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells.
    Cao C; Subhawong T; Albert JM; Kim KW; Geng L; Sekhar KR; Gi YJ; Lu B
    Cancer Res; 2006 Oct; 66(20):10040-7. PubMed ID: 17047067
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.
    Liu H; Scholz C; Zang C; Schefe JH; Habbel P; Regierer AC; Schulz CO; Possinger K; Eucker J
    Anticancer Res; 2012 May; 32(5):1627-37. PubMed ID: 22593441
    [TBL] [Abstract][Full Text] [Related]  

  • 31. First-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Harshman LC; Kroeger N; Rha SY; Donskov F; Wood L; Tantravahi SK; Vaishampayan U; Rini BI; Knox J; North S; Ernst S; Yuasa T; Srinivas S; Pal S; Heng DY; Choueiri TK
    Clin Genitourin Cancer; 2014 Oct; 12(5):335-40. PubMed ID: 24787966
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical development of mTOR inhibitors: a focus on lymphoma.
    Smith SM
    Rev Recent Clin Trials; 2007 May; 2(2):103-10. PubMed ID: 18473994
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibitors of mTOR.
    Klümpen HJ; Beijnen JH; Gurney H; Schellens JH
    Oncologist; 2010; 15(12):1262-9. PubMed ID: 21147869
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibitors of the mTOR signaling pathway can play an important role in breast cancer immunopathogenesis.
    Al-Hawary SIS; Altalbawy FMA; Jasim SA; Jyothi S R; Jamal A; Naiyer MM; Mahajan S; Kalra H; Jawad MA; Zwamel AH
    Cell Biol Int; 2024 Nov; 48(11):1601-1611. PubMed ID: 39164963
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
    Serova M; de Gramont A; Tijeras-Raballand A; Dos Santos C; Riveiro ME; Slimane K; Faivre S; Raymond E
    Cancer Chemother Pharmacol; 2013 May; 71(5):1297-307. PubMed ID: 23479136
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting mTOR signaling pathway in ovarian cancer.
    Mabuchi S; Hisamatsu T; Kimura T
    Curr Med Chem; 2011; 18(19):2960-8. PubMed ID: 21651485
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel Pyrazino[2,3-b] Pyrazines as mTOR Kinase Inhibitors for Treating Cancer and other Diseases.
    De SK
    Curr Med Chem; 2024; 31(34):5657-5659. PubMed ID: 37493157
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rapamycin protection of livers from ischemia and reperfusion injury is dependent on both autophagy induction and mammalian target of rapamycin complex 2-Akt activation.
    Zhu J; Lu T; Yue S; Shen X; Gao F; Busuttil RW; Kupiec-Weglinski JW; Xia Q; Zhai Y
    Transplantation; 2015 Jan; 99(1):48-55. PubMed ID: 25340604
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of mTOR during cisplatin treatment in an in vitro and ex vivo model of cervical cancer.
    Leisching GR; Loos B; Botha MH; Engelbrecht AM
    Toxicology; 2015 Sep; 335():72-8. PubMed ID: 26201060
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [mTOR inhibitors, autophagia and Cancer: looking forward to a universal financial coverage].
    Arancibia J; Labbé TP; Ríos JA
    Rev Med Chil; 2019 May; 147(5):674-676. PubMed ID: 31859903
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.